J&J, Elan Sign Agreement For Alzheimer’s Immunotherapy Program
Johnson & Johnson (J&J) and Elan have signed an agreement whereby J&J (through a newly formed company) will acquire all the assets and rights of Elan related to
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Schering-Plough has announced the results from the Phase III Engage clinical trial demonstrating that a single injection of corifollitropin alfa, achieved similar efficacy to recombinant follicle stimulating hormone